

CONTENTS

Opening address of the President of the International Society of Hypertension. JAMES O. DAVIS	1s
Welcome by the Chairman of the Organizing Committee. ALBERTO ZANCHETTI	2s
Awards Ceremony Address. JAMES O. DAVIS	3s
I. Sodium ions, membrane transport and hypertension	
State of the Art Review: Membranes, ions and hypertension. D. C. TOSTESON, N. ADRAGNA, I. BIZE, H. SOLOMON and M. CANESSA	5s
K_1^+ - Na_0^+ countertransport in erythrocytes of patients with essential hypertension. N. ADRAGNA, M. CANESSA, I. BIZE, H. SOLOMON and D. C. TOSTESON	11s
Increased erythrocyte lithium-sodium countertransport in essential hypertension: its relationship to family history of hypertension. M. CANALI, L. BORGH, E. SANI, A. CURTI, A. MONTANARI, A. NOVARINI and A. BORGHETTI.	13s
An increase in a circulating inhibitor of Na^+, K^+ -dependent ATPase: a possible link between salt intake and the development of essential hypertension. G. A. MACGREGOR, S. FENTON, J. ALAGHBAND-ZADEH, N. D. MARKANDU, J. E. ROULSTON and H. E. DE WARDENER	17s
Effects of a low-salt diet and of acute salt loading on blood pressure and intralym- phocytic sodium concentration in young subjects with borderline hypertension. F. V. COSTA, E. AMBROSIONI, L. MONTEBUGNOLI, L. PACCALONI, L. VASCONI and B. MAGNANI	21s
Intralymphocytic sodium concentration as an index of response to stress and exercise in young subjects with borderline hypertension. E. AMBROSIONI, F. V. COSTA, L. MONTEBUGNOLI, C. BORGH, and B. MAGNANI	25s
Dietary sodium, erythrocyte sodium concentration, sodium-stimulated lithium efflux and blood pressure. M. TREVISAN, R. COOPER, D. OSTROW, W. MILLER, S. SPARKS, Y. LEONAS, A. ALLEN, M. STEINHAEUER and J. STAMLER	29s
Relationship between altered Na^4-K^+ cotransport and Na^+-Li^+ countertransport in the erythrocytes of 'essential' hypertensive patients. D. CUSI, C. BARLASSINA, M. FERRANDI, P. PALAZZI, E. CELEGA and G. BIANCHI	33s
Effect of acute and chronic salt loading on erythrocyte ^{22}Na efflux in males with essential hypertension. J. B. MYERS, W. R. FITZGIBBON and T. O. MORGAN	37s
Intracellular cation activities and concentrations in spontaneously hypertensive and normotensive rats. W. ZIDEK, H. VETTER, H. ZUMKLEY and H. LOSSE	41s
Abnormal calcium handling by isolated cardiac plasma membrane from spontaneously hypertensive rats. MARIE-GABRIELLE PERNOLLET, MARIE-AUDE DEVYNCK and P. MEYER	45s

Paraventricular-suprachiasmatic lesions prevent salt-induced hypertension in Dahl rats. SILVIA AZAR, P. ERNSBERGER, SUZANNE LIVINGSTON, P. AZAR and J. IWAI	49s
Brain lesions in the paraventricular nuclei and catecholaminergic neurons minimize salt hypertension in Dahl salt-sensitive rats. A. GOTO, T. IKEDA, L. TOBIAN, J. IWAI and MARY A. JOHNSON	53s
Studies on the role of a humoral sodium-transport inhibitor and the anteroventral third ventricle (AV3V) in experimental low-renin hypertension. M. B. PAMNANI, J. BUGGY, S. J. HUOT and F. J. HADDY	57s
Chemical denervation does not affect the medial hypertrophy and increased calcium sensitivity of mesenteric resistance vessels from spontaneously hypertensive rats. M. J. MULVANY, N. KORSGAARD, N. NYBORG and H. NILSSON	61s
Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man. J. A. MILLAR, KATHLEEN MCLEAN and J. L. REID	65s
Partial replacement of sodium by potassium in the diet restores impaired noradrenaline inactivation and lowers blood pressure in stroke-prone spontaneously hypertensive rats. R. DIETZ, A. SCHÖMIG, W. RASCHER, R. STRASSER, U. GANTEN and W. KÜBLER	69s
Potassium citrate feeding protects against nephron loss in severe sodium chloride hypertension in rats. M. GANGULI, L. TOBIAN, J. IWAI and MARY ANN JOHNSON	73s
Studies on the hypotensive effect of high potassium intake in patients with essential hypertension. OSAMU IIMURA, TOSHIAKI KIJIMA, KENJIRO KIKUCHI, AKIYOSHI MIYAMA, TOSHIAKI ANDO, TAKASHI NAKAO and YOSHIICHI TAKIGAMI	77s
Relation of arterial pressure with exchangeable and total body sodium and with plasma exchangeable and total body potassium in essential hypertension. C. BERETTA-PICCOLI, D. L. DAVIES, K. BODDY, J. J. BROWN, A. M. M. CUMMING, W. B. EAST, R. FRASER, A. F. LEVER, P. PADFIELD, J. I. S. ROBERTSON, P. WEIDMANN and E. D. WILLIAMS	81s
Blood pressure and plasma sodium and potassium. C. J. BULPITT, M. J. SHIPLEY and A. SEMMENCE	85s
II. Haemodynamics	
Haemodynamic effects of noise exposure before and after β_1 -selective and non-selective β -adrenoceptor blockade in patients with essential hypertension. L. ANDRÉN, L. HANSSON and M. BJÖRKMAN	89s
Possible relationship between psycho-emotional factors and haemodynamic patterns in the pathogenesis of mild blood pressure elevation. S. JERN, R. SIVERTSSON and L. HANSSON	93s
Time-course of vascular resistance changes in mineralocorticoid hypertension of man. G. J. WENTING, A. J. MAN IN 'T VELD and M. A. D. H. SCHALEKAMP	97s
The relationship between ambulatory blood pressure and echocardiographically assessed left ventricular hypertrophy. D. B. ROWLANDS, M. A. IRELAND, D. R. GLOVER, R. A. B. MCLEAY, T. J. STALLARD and W. A. LITTLER	101s
Factors influencing cardiac hypertrophy in hypertensive patients. M. MOHSEN IBRAHIM, M. AZIZ MADKOUR and RAGAA MOSSALLAM	105s

Left ventricular hypertrophy improves cardiac function in spontaneously hypertensive rats. S. LUNDIN, P. FRIBERG and M. HALLBÄCK-NORLANDER	109s
Combined pre- and after-load reduction in hypertensive patients with cardiomegaly and normal filling pressure. S. N. HUNYOR, G. I. NELSON and G. L. DONNELLY	113s
Haemodynamic changes after surgical reversal of chronic two-kidney, one-clip hypertension in the rat. G. I. RUSSELL, J. M. BRICE, R. F. BING, J. D. SWALES and H. THURSTON	117s
Mechanisms of structural vascular changes in genetic hypertension: analyses on cultured vascular smooth muscle cells from spontaneously hypertensive rats. YUKIO YAMORI, TAKEHIRO IGAWA, TOSHIMI KANBE, MASAHIRO KIHARA, YASUO NARA and RYOICHI HORIE	121s
Extent of structurally reduced venous distensibility in rats. HOLGER NILSSON, BÖRJE HARALDSSON and BJÖRN FOLKOW	125s
III. Vasopressin	
State of the Art Review: Role of vasopressin in cardiovascular homeostasis and hypertension. C. I. JOHNSTON, M. NEWMAN and R. WOODS	129s
Does vasopressin play a role in the pathogenesis of hypertension? P. L. PADFIELD, J. J. BROWN, A. F. LEVER, J. J. MORTON and J. I. S. ROBERTSON	141s
The reflex control of arginine-vasopressin release in essential hypertension. B. RICCIARDELLI, M. VOLPE, B. TRIMARCO, M. CHIARIELLO, F. RENGO and MARIO CONDORELLI	145s
Abnormalities and drug-induced alterations of vasopressin in human hypertension. M. THIBONNIER, J. C. ALDIGIER, M. E. SOTO, P. SASSANO, J. MENARD and P. CORVOL	149s
Vasopressin-induced increase in total peripheral resistance in deoxycorticosterone acetate hypertensive rats is buffered by the baroreceptor reflex. W. RASCHER, R. E. LANG, M. TAUBITZ, H. MEFFLE, TH. UNGER, D. GANTEN and F. GROSS	153s
IV. Catecholamines and the sympathetic nervous system	
Daily profile of baroreflex sensitivity and the variability of blood pressure in essential hypertensive patients. JUN OGAWA, SHIRO ARAI, SHIGEO TAKATA, TAKAYUKI IKEDA, TOSHIKAZU TAKABATAKE, NOBU HATTORI and GAKUJI NOMURA	157s
Elevated plasma adrenaline reflects sympathetic overactivity and enhanced α -adrenoceptor-mediated vasoconstriction in essential hypertension. P. BOLLI, F. W. AMANN, L. HULTHÉN, W. KIOWSKI and F. R. BÜHLER	161s
Plasma noradrenaline as a measure of baroreflex sensitivity in hypertensive man. A. M. M. SHEPHERD, M.-S. LIN, T. K. KEETON and J. L. MCNAY	165s
Reflex control of sympathetic nerve activity and heart rate from arterial baroreceptors in conscious spontaneously hypertensive rats. S. E. RICKSTEN and P. THORÉN	169s
Blood volume and the carotid baroreceptor reflex in conscious rabbits. J. LUDBROOK, I. B. FARIS and G. G. JAMIESON	173s
Contribution of cardiovascular reflexes to differences in β -adrenoceptor-mediated responses in essential hypertension. G. JENNINGS, A. BOBIK, M. ESLER and P. KORNER	177s

A sympathetic hypertensive reflex from the heart of conscious dogs. M. PAGANI, P. PIZZINELLI, R. FURLAN, S. GUZZETTI, O. RIMOLDI and A. MALLIANI	181s
Regression of the baroreceptor resetting in hypertension of long duration in rats. MARIE SUMITANI and E. M. KRIEGER	185s
Adrenergic components of hypertension after renal transplantation. R. S. SMITH, J. L. REID and D. J. WARREN	187s
Adrenaline-induced hypertension in rats. L.-H. TUNG, M. J. RAND and H. MAJEWSKI	191s
Role of the sympathetic nervous system in spontaneous hypertension: changes in central adrenoceptors and plasma catecholamine levels. ANNA PALERMO, CARLO COSTANTINI, GABRIELE MARA and ARNALDO LIBRETTI	195s
Plasma concentrations of catecholamines in two strains of spontaneously hypertensive rats at different ages. P. FERRARI, G. B. PICOTTI, E. MINOTTI, G. P. BONDILOTTI, A. M. CARAVAGGI and G. BIANCHI	199s
Heterogeneity of human vascular pre- and post-synaptic α -adrenoceptors. M. J. STEVENS, R. E. RITTINGHAUSEN and R. F. W. MOULDS	203s
Endogenous agonist regulation of α -adrenoceptors in man. I. B. DAVIES, D. SUDERA and P. S. SEVER	207s
Noradrenaline reactivity in patients with phaeochromocytoma before and after surgical correction. G. LEONETTI, L. TERZOLI, G. BIANCHINI, L. RUPOLI, R. LIPIRA and A. ZANCHETTI	211s
Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? S. E. KJELDSSEN, B. FLAATEN, I. EIDE, A. HELGELAND and P. LEREN	215s
Adrenaline neurons and PNMT activity in the brain and spinal cord of genetically hypertensive rats and rats with DOCA-salt hypertension. J. P. CHALMERS, P. R. C. HOWE, Y. WALLMANN and I. TUMULS	219s
Excitatory effect of converting enzyme inhibitors on efferent sympathetic post-ganglionic nerve activity to the kidney in the rat. G. RECORDATI, S. GENOVESI, D. CERATI, R. DI CINTIO and P. GEROMETTA	223s
Differences <i>in utero</i> in activities of catecholamine biosynthetic enzymes in adrenals of spontaneously hypertensive rats. G. TEITELMAN, R. A. ROSS, T. H. JOH and D. J. REIS	227s
Central dopaminergic mechanism in young patients with essential hypertension. R. E. KOLLOCH, K. O. STUMPE, V. DEQUATTRO, U. ISMER and O. KLETZKY	231s
Role of dopamine in the regulation of blood pressure and the renin-angiotensin-aldosterone system in conscious rats. KAZUOKI KONDO, AKIO EBIHARA, HIROMICHI SUZUKI and TAKAO SARUTA	235s
V. Renin-angiotensin-aldosterone system	
A monoclonal antibody for immunopurification of human renin. B. PAU, D. SIMON, F. X. GALEN, C. DEVAUX, F. SOUBRIER, J. MÉNARD and P. CORVOL	239s
Studies of the biosynthesis of renin with a cell-free translation system. V. J. DZAU, A. OUELLETTE and R. PRATT	241s

Specific nuclear binding of angiotensin II by rat liver and spleen nuclei. R. N. RE, A. A. MACPHEE and J. T. FALLON	245s
Distribution and properties of angiotensin-converting enzyme in cerebral microvessels of the rabbit and rat. P. BRECHER, V. HINGORANI, K. REININGA and A. V. CHOBANIAN	249s
Immunological and immunofluorescent studies of human angiotensin-converting enzyme. Y. TAKADA, M. UNNO, K. HIWADA and T. KOKUBU	253s
Aggression-provoked renin release from an unknown source in male mice. K. POULSEN and E. B. PEDERSEN	257s
Blood pressure and the renin-angiotensin-aldosterone system. S. LJUNGMAN, M. AURELL, M. HARTFORD, J. WIKSTRAND and G. BERGLUND	261s
Relationship between plasma renin and cortisol in hypertensive patients. S. A. ATLAS, D. B. CASE, J. E. SEALEY and J. H. LARAGH	265s
Blood pressure, renal and metabolic effects of ACTH in normotensive man. J. A. WHITWORTH, D. SAINES, R. THATCHER, A. BUTKUS, B. A. SCOGGINS and J. P. COGHLAN	269s
ACTH stimulates plasma renin and angiotensin II in man. W. OELKERS, A. KÖHLER, L. BELKIEN, R. FUCHS-HAMMOSER, M. MAIGA, B. SCHERER and P. C. WEBER	273s
Complex competitive and non-competitive inhibition of rat lung angiotensin-converting enzyme by inhibitors containing thiol groups: captopril and SA 446. F. A. O. MENDELSON, J. CSICSMANN and J. S. HUTCHINSON	277s
Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension. H. GAVRAS, J. BIOLLAZ, B. WAEBER, H. R. BRUNNER, I. GAVRAS, H. SACKEL, F. CHAROCOPOS and R. O. DAVIES	281s
Effect of converting enzyme inhibition on the systemic and renal responses to acute isotonic volume expansion in normal man. A. MIMRAN and J. RIBSTEIN	285s
Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. F. MANTERO, F. FALLO, G. OPOCHER, D. ARMANINI, M. BOSCARO and C. SCARONI	289s
Two forms of plasma renin after activation <i>in vitro</i> and their relation to natural plasma renin. F. H. M. DERKX, M. P. A. SCHALEKAMP and M. A. D. H. SCHALEKAMP	295s
Activation of renin in an anaplastic pulmonary adenocarcinoma. F. SOUBRIER, S. L. SKINNER, M. MIYAZAKI, J. GENEST, J. MÉNARD and P. CORVOL	299s
Optimum tryptic activation of inactive renin in human plasma is independent of endogenous anti-tryptic activity. A. RAPPELLI, P. DESSI-FULGHERI, P. MAEDDU, F. MELONI, C. FIORI, G. SANNA and N. GLORIOSO	303s
α_1 -Adrenoceptor blockade: dissociation of its effects on renin release and arterial blood pressure in man. A. MORGANTI, C. SALA, A. PALERMO, L. TUROLO and A. ZANCHETTI	307s
α -Adrenoceptors and age-dependent decrease of plasma renin activity in essential hypertension. A. SALVETTI, R. PEDRINELLI, F. ARZILLI, P. SASSANO, G. LEONETTI, L. TERZOLI, C. BIANCHINI and M. FRUSCIO	311s

VI. Prostaglandin, kallikrein and other systems

- Vasodepressor effects of arachidonic acid and prostacyclin (PGI₂) in hypertensive rats.
G. J. DUSTING, R. DI NICOLANTONIO, T. DRYSDALE and A. E. DOYLE 315s
- Are prostaglandins involved in the antihypertensive effect of dihydralazine? I. W.
REIMANN, D. RATGE, H. WISSER and J. C. FRÖLICH 319s
- Central haemodynamics and plasma prostaglandin E₂ in borderline and sustained
essential hypertensive patients before and after indomethacin. M. E. SAFAR,
A. F. HORNYCH, J. A. LEVENSON, A. CH. SIMON, G. M. LONDON, J. L. BARIETY
and P. L. MILLIEZ 323s
- Exaggerated fractional sodium excretion in hypertension with advanced renal disease:
the role of renal prostaglandin and kallikrein. K. ABE, Y. IMAI, M. SATO, T.
HARUYAMA, K. SATO, M. HIWATARI, Y. KASAI, S. ITOH, M. YASUJIMA, M.
SEINO and K. YOSHINAGA 327s
- Derivation of neutral antihypertensive lipid from renal venous effluent in rats. E. E.
MUIRHEAD, L. W. BYERS, J. A. PITCOCK, D. M. DESIDERIO, B. BROOKS,
P. BROWN and W. L. BROSIUS 331s
- Chemical renal medullectomy; effect upon reversal of two-kidney, one-clip hyper-
tension in the rat. R. F. BING, G. I. RUSSELL, J. D. SWALES, H. THURSTON and
A. FLETCHER 335s
- β -Endorphin, an endogenous depressor agent in the rat? M. A. PETTY, J. M. A.
SITSEN and W. DE JONG 339s
- Effects of bromocriptine on blood pressure and plasma β -endorphin in spontaneously
hypertensive rats. J. S. HUTCHINSON, R. DI NICOLANTONIO, A. LIM, J. CLEMENTS
and J. W. FUNDER 343s
- Central peptidergic stimulation in blood pressure control: role of enkephalins in rats.
T. YUKIMURA, T. UNGER, W. RASCHER, R. E. LANG and D. GANTEN 347s
- Kallikrein and renin: molecular biology and biosynthesis. B. J. MORRIS, D. F.
CATANZARO, R. I. RICHARDS, A. MASON and J. SHINE 351s
- Experimental essential hypertension in the rat? M. NOWACZYNSKI, W. NOWACZYNSKI,
D. MAVOUNGOU, G. WILKINS, K. FUNG and R. BOYKO 355s

VII. Clinical aspects

- Influence of family history of hypertension on the relationships between blood
pressure, body weight, electrolyte metabolism, renin, prolactin and parathormone.
F. WESSELS, D. HOFFMANN, H. WAGNER and H. ZUMKLEY 359s
- Association between the C3^F-gene and essential hypertension. O. SCHAADT, H.
SØRENSEN and A. R. KROGSGAARD 363s
- HLA antigens in Spanish patients with essential hypertension. A. FERNANDEZ-CRUZ,
Jr, M. LUQUE OTERO, L. LLORENTE PEREZ, C. FERNANDEZ PINILLA and N.
MARTELL CLAROS 367s
- Hypertension, cerebrovascular disease and stomach cancer: is the salt hypothesis true?
P. K. WHELTON and P. GOLDBLATT 369s
- Alcohol: effect on blood pressure and predisposition to hypertension. P. D.
ARKWRIGHT, L. J. BEILIN, I. ROUSE, B. K. ARMSTRONG and R. VANDONGEN 373s

The influence of chronic high alcohol intake on blood pressure, plasma noradrenaline concentration and plasma renin concentration. H. IBSEN, N. J. CHRISTENSEN, S. RASMUSSEN, H. HOLLNAGEL, M. DAMKJAER NIELSEN and J. GIESE	377s
Does long-term low-dose corticosteroid therapy cause hypertension? S. H. D. JACKSON, D. G. BEEVERS and K. MYERS	381s
Neurohumoral response to hospitalization in hypertensive patients. P. W. DE LEEUW, G. A. W. VAN SOEST, R. PUNT, R. P. L. M. HOOGMA, A. J. P. M. SMOUT and W. H. BIRKENHÄGER	385s
Anger, anxiety, guilt and increased basal and stress-induced neurogenic tone: causes or effects in primary hypertension? P. A. SULLIVAN, W. R. PROCCI, V. DEQUATTRO, S. SCHOENTGEN, D. LEVINE, J. VAN DER MEULEN and J. F. BORNHEIMER	389s
Hypertension in the elderly: haemodynamic, fluid volume and endocrine findings. F. H. MESSERLI, L. B. GLADE, G. R. DRESLINSKI, F. G. DUNN, E. REISIN, A. A. MACPHEE and E. D. FROHLICH	393s
Response of patients with renal involvement by progressive systemic sclerosis to anti-hypertensive therapy. Y. M. TRAUB, A. P. SHAPIRO, T. A. OSIAL, Jr, G. P. RODNAN, T. A. MEDSGER, D. E. LEB and W. C. CHRISTY	395s
Accuracy of the London School of Hygiene and Remler M2000 sphygmomanometers. D. J. FITZGERALD, W. G. O'CALLAGHAN, K. O'MALLEY and E. T. O'BRIEN	399s
VIII. Therapeutic aspects	
State of the Art Review: The problem of treatment in mild hypertension. W. S. PEART	403s
State of the Art Review: Does it matter how blood pressure is reduced? C. T. DOLLERY	413s
Haemodynamic effects of withdrawal of long-term treatment with β -adrenoceptor blocking agents in subjects with essential hypertension. C. BENGTSSON, Y. LARSSON, V. PANFILOV, R. SIVERTSSON and H. ÅSTRÖM	421s
Metoprolol and pindolol in hypertension: different effects on peripheral haemodynamics. A. SVENSSON, T. GUDBRANDSSON, R. SIVERTSSON and L. HANSSON	425s
Effects of combined α - and β -receptor blockade on peripheral circulation in essential hypertension. I. HECK, G. TRÜBESTEIN and K. O. STUMPE	429s
Effects of short-term and long-term treatment with cardioselective and non-selective β -receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. G. KOCH, I.-W. FRANZ and F. W. LOHMANN	433s
β -Receptor-blocking agents may reverse or prevent diuretic-induced increases in serum low-density lipoprotein cholesterol. A. MEIER, H. SCHIFFL, P. WEIDMANN, R. MORDASINI, W. RIESEN and C. BACHMANN	437s
The hypotensive effect of propranolol in captopril-treated patients does not involve the plasma renin-angiotensin-aldosterone system. J. STAESSEN, R. FAGARD, P. LUNEN, L. J. VERSCHUEREN and A. AMERY	441s
Decrease in α -adrenoceptor-mediated vasoconstriction parallels the antihypertensive response to propranolol in patients with normal renin essential hypertension. F. W. AMANN, P. BOLLI, L. HULTHÉN, W. KIOWSKI and F. R. BÜHLER	445s
An analysis of the blood pressure response to labetalol in hypertensive patients. J. J. MCNEIL, A. E. ANDERSON and W. J. LOUIS	449s

Lack of antagonism in the antihypertensive effects of clonidine and prazosin in man. M. ANDRÉJAK, P. FIEVET, R. MAKDASSI, E. COMOY, J. F. DE FREMONT, B. COEVOET and A. FOURNIER	453s
The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man. D. MCAREAVEY, A. M. M. CUMMING, V. P. SOOD, B. J. LECKIE, J. J. MORTON, G. D. MURRAY and J. I. S. ROBERTSON	457s
Prizidilol (SKF 92 657) in primary hypertension. B. E. KARLBERG, R. LARSSON and K. P. OHMAN	461s
Effects of prizidilol (SKF 92 657) on blood pressure, haemodynamics, sympathetic nervous system activity and plasma volume in essential hypertension. R. FARIELLO, C. L. ALICANDRI, E. AGABITI-ROSEI, G. ROMANELLI, M. CASTELLANO, M. BESCHI, L. PLATTO, S. LETO DI PRIOLO and G. MUIESAN	465s
Antihypertensive effect of guanfacine: long-term 'once-a-day' treatment and sudden withdrawal. I. SZÁM and J. HOLLÓ	469s
The antihypertensive effects of ketanserin (R 41 468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension. J. DE CRÉE, J. LEEMPOELS, H. GEUKENS, W. DE COCK and H. VERHAEGEN	473s
BM 12.434, a novel compound with vasodilating and β -adrenoceptor-blocking activities. E. VON MÖLLENDORFF, C. HUSCHKA, E. SCHRÖTER and U. ABSHAGEN	477s
Percutaneous transluminal dilatation of renal artery stenosis: 2 years' experience. U. KUHLMANN, W. VETTER, A. GRÜNTZIG, E. SCHNEIDER, G. POULIADIS, J. STEURER and W. SIEGENTHALER	481s
Percutaneous transluminal dilatation or surgery in the management of renal vascular hypertension? C. E. GRIM, H. Y. YUNE, M. H. WEINBERGER and J. P. DONOHUE	485s
Can placebo therapy influence arterial blood pressure? B. A. GOULD, S. MANN, A. B. DAVIES, D. G. ALTMAN and E. B. RAFTERY	487s
IX. End of Meeting	
Address on the occasion of the Official Dinner at the Eighth Meeting of the International Society of Hypertension by the Chairman of the Organizing Committee. A. ZANCHETTI	491s
President's remarks at the banquet. J. O. DAVIS	493s
Author Index	495s

These proceedings are once more being published as a supplement to *Clinical Science*. Papers have been edited by a team comprising Hans Brunner, James Conway, Robert Fraser, Charles George, Frank Goodwin, John Vann Jones, Michael Lee, John Reid, Ian Robertson and Peter Sever. We are, as ever, grateful to them, to the Editorial Office of *Clinical Science* under Tony Evans and to my secretary Miss Anne Taylor. The hard work they have put in has once more enabled authors to see their work appearing within a short time of presentation in a volume which, judging by previous experience, will be much studied and cited.

JOHN SWALES

Acknowledgment

The generous support of E. R. Squibb and Sons Inc. towards the cost of publication of these proceedings is gratefully acknowledged.